Physician profile
Lawrence H Byrd
NPI 1619916756
$337,865.90
in general payments reported to CMS, 2019-2025
22 companies · $31K in 2025
The $31K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,660 · 2021: $58K · 2022: $80K · 2023: $38K · 2024: $115K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $146K · Travel and Lodging: $34K · Food and Beverage: $3,310 · Consulting Fee: $185 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,858.00 |
| Travel and Lodging | $33,694.19 |
| Food and Beverage | $3,309.72 |
| Consulting Fee | $185.00 |
| Education | $118.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $294,217.72 | 2021-2025 | |
| Vifor Pharma, INC. | $41,304.31 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $1,307.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $185.00 | 2023 | Benlysta |
| Arbor Pharmaceuticals, INC. | $120.38 | 2019 | |
| Travere Therapeutics, INC. | $96.49 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $85.23 | 2019 | |
| Amgen INC. | $75.46 | 2019 | |
| Horizon Therapeutics Plc | $70.72 | 2019 | |
| Alexion Pharmaceuticals, INC. | $51.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $49.79 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $42.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $42.42 | 2019-2021 | |
| Genentech USA, INC. | $41.29 | 2019 | |
| Daiichi Sankyo INC. | $39.65 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $35.98 | 2019 | |
| Calliditas Therapeutics US INC. | $26.67 | 2025 | Tarpeyo |
| Akebia Therapeutics INC | $21.68 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.89 | 2025 | Edarbi |
| Hikma Pharmaceuticals USA | $12.75 | 2019 | |
| Amarin Pharma, INC. | $11.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.